Pure Global
NCT05073263

Full Vs Partial Weightbearing During the First Six Weeks of Rehab. After Fibular Collateral Ligament Reconstruction

Full Weightbearing Versus Partial Controlled Weightbearing During the First Six Weeks of Rehabilitation After Reconstruction of the Fibular Collateral Ligament: A Randomized Controlled Trial
Twin Cities Orthopedics·ClinicalTrials.gov·otherRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Knee Injuries
Drug/Device/Intervention
Physical Therapy
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
Twin Cities Orthopedics
Location
Edina, United States of America
Timeline & enrollment
Phase
N/A
Start date
Jan 01, 2020
End date
Jan 01, 2026
Enrollment
50 participants
Primary outcome

Gapping (mm) measured on Standard of Care Varus stress radiographs,Gapping (mm) measured Standard of Care Varus stress radiographs

Summary

This is a prospective randomized controlled trial with the purpose to determine if patients
 undergoing fibular collateral ligament (FCL) reconstruction alone or combined FCL and
 anterior cruciate ligament (ACL) reconstructions can safely begin full controlled
 weightbearing for the first six weeks after surgery.

ICD-10 classifications
Injuries to the knee and lower legSprain and strain of other and unspecified parts of kneeOther spontaneous disruption of ligament(s) of kneeCrushing injury of kneeInjury to multiple structures of knee
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05073263
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05073263 through Pure Global AI's free database. This phase not specified trial is sponsored by Twin Cities Orthopedics and is currently Recruiting. The study focuses on Knee Injuries. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.